DIS3L Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HGC-27 human gastric adenocarcinoma cell line. This product features targeted disruption of the DIS3L gene, providing a loss-of-function model for studying the roles of the cytoplasmic exosome catalytic subunit. The polyclonal format represents a heterogeneous pool of edited cells, enabling robust population-level analyses without clonal selection bias and is suitable for transcriptomic and functional assays.
The HGC-27 parental cell line is an adherent epithelial model established from a lymph node metastasis of a gastric adenocarcinoma. It is widely utilized to investigate molecular mechanisms of gastric cancer progression, including proliferation, invasion, and metastasis. The cell line retains aggressive tumor features, making it a clinically relevant platform to assess the impact of DIS3L deletion on oncogenic phenotypes and RNA metabolism dysregulation.
DIS3L encodes the essential 3′-5′ exoribonuclease of the cytoplasmic RNA exosome, a macromolecular complex that processes and degrades diverse RNA species. DIS3L directly interacts with exosome core components EXOSC1-10 and cofactors SKIV2L and EXOSC10 to catalyze the removal of poly(A) tails and subsequent RNA decay. This activity is central to mRNA surveillance pathways, including nonsense-mediated decay, and regulates the stability of transcripts encoding oncoproteins and tumor suppressors, thereby modulating gene expression in response to cellular cues.
In HGC-27 cells, knockout of DIS3L disrupts cytoplasmic RNA turnover, leading to accumulation of normally short-lived mRNAs and potential rewiring of signaling networks. This perturbation offers a unique opportunity to explore how impaired RNA surveillance contributes to gastric adenocarcinoma cell behavior, including altered proliferation rates, apoptosis resistance, and enhanced metastatic capacity. The model may aid in identifying RNA substrates whose misregulation drives gastric cancer malignancy.
Researchers can employ this knockout product in RNA-seq and qRT-PCR experiments to identify stabilized transcripts, cell proliferation and apoptosis assays to measure functional outcomes, and migration/invasion assays to evaluate metastatic potential. Western blotting and co-immunoprecipitation can validate protein expression changes and interactions with exosome components. For additional information or to discuss custom applications, please contact Ascent Research.
